Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03540030 · ClinicalTrials.gov registry record · Phase 4

Opioid-Free Shoulder Arthroplasty

A Phase 4 study of Opioid Use and Avascular Necrosis, sponsored by OrthoCarolina Research Institute.

Completed
Registry status
Phase 4
Development phase
86
Enrollment target
1
Study location

NCT03540030 is a Phase 4 study of Opioid Use and Avascular Necrosis that has completed, run by OrthoCarolina Research Institute. The registered enrollment target is 86 participants, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03540030, a Phase 4 study of Opioid Use and Avascular Necrosis, has completed, sponsored by OrthoCarolina Research Institute.

COMPLETED
Registry status
Phase 4
Development phase
86 participants
Enrollment target
1
Study location

Study Summary

Purpose of Study: To identify and provide a safe, opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

Interventions

  • DRUG Celecoxib
  • DRUG Gabapentin
  • DRUG acetaminophen
  • DRUG toradol
  • DRUG regional block

Study Locations (1)

North Carolina

  • OrthoCarolina Research Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2016-09
Est. Completion 2019-06
Phase Phase 4

Sponsor

OrthoCarolina Research Institute

28 total trials

What the Registry Record Tells You About NCT03540030

The ClinicalTrials.gov registry entry for NCT03540030 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The listed sponsor is OrthoCarolina Research Institute, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Opioid Use appearing as the primary indexed condition, and to 5 interventions - of which Celecoxib is the first listed.

NCT03540030 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03540030 about?

NCT03540030 is a clinical study titled "Opioid-Free Shoulder Arthroplasty". Purpose of Study: To identify and provide a safe, opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment

What is the current status of trial NCT03540030?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2016-09. Estimated completion is 2019-06.

What conditions does trial NCT03540030 study?

This clinical trial studies the following conditions: Opioid Use, Avascular Necrosis, Rotator Cuff Tear, Shoulder Osteoarthritis, Arthritis;Inflammatory.

What interventions are being tested in trial NCT03540030?

The interventions under investigation include: Celecoxib (DRUG), Gabapentin (DRUG), acetaminophen (DRUG), toradol (DRUG), regional block (DRUG).

Who is sponsoring clinical trial NCT03540030?

This trial is sponsored by OrthoCarolina Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03540030 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.